Objectives: The results of many clinical trials demonstrate the benefit of longterm antiplatelet therapy in reducing the risk of cardio-and cerebrovascular complications. Both acetylsalicylic acid (ASA) and clopidogrel are effective, but have potentially serious side effects, and clopidogrel is more expensive than ASA. The purpose of the study is to evaluate the pharmacoeconomic acceptance of clopidogrel versus ASA in patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease to prevent non-fatal stroke and death rate according to the clinical trial CAPRIE from Ukrainian perspective. MethOds: Outcomes of the clinical study CAPRIE, modeling "decision tree" and analysis "cost-effectiveness" were used. Results: The results of the clinical trial CAPRIE study showed, that clopidogrel is more effective versus ASA for reducing the risk of nonfatal stroke: absolute risk reduction is -2.7%. Model "decision tree" was built using the probabilities of events (nonfatal stroke and death) from the study CAPRIE. Direct costs were calculated taking into account the costs of antiplatelet therapy, of nonfatal stroke treatment (drugs, diagnosis, patient's stay in hospital) and the cost of rehabilitation after stroke. Indirect costs are not taken into account because the patients were of retirement age (62.5 years old). As a result of calculations it was found, that antiplatelet therapy with clopidogrel is more expensive and more effective (2 additional lives saved per 1000 patients over 1.91 years) compared with ASA. Due to the threshold of society "willingness to pay" per 1 life saved, or 1 QALY, use of clopidogrel as antiplatelet agent in patients with cardiovascular disease is economically profitable for Ukraine. cOnclusiOns: The use of clopidogrel as an antiplatelet agent in patients with cardiovascular disease to prevent nonfatal stroke compared to the ASA is economically profitable for Ukraine. Objectives: Stroke and its associated disability costs the European Union an estimated € 62 billion per year. Warfarin is the mainstay for stroke prevention in atrial fibrillation (AF), but many patients have absolute contraindications to this drug. The Watchman device for left atrial appendage closure (LAAC) received CE mark for stroke prevention in AF patients with contraindications to warfarin. This analysis sought to estimate the cost effectiveness of treating warfarin-ineligible AF patients with LAAC as compared to standard aspirin therapy. MethOds: A Markov model was developed comparing clinical outcomes and total costs between patients treated with LAAC or aspirin over 5 and 10 years based largely on clinical outcomes from the Aspirin and Plavix Registry (ASAP) and ACTIVE trials. Clinical events included ischemic stroke, TIA, systemic embolism, bleeding, and acute myocardial infarction as well as procedure-related events. Germany was chosen as the country of analysis because of its unique DRG for the LAAC procedure. Acute costs were taken from German DRGs and long-term disability costs were taken from the Berlin Acute Stroke Study. Sensitivity analysis was performed on clinical and cost inputs; the model was most sensitive to changes in the rate of ischemic stroke. Results: LAAC demonstrated a benefit in terms of ischemic strokes and mortality avoided. The cost per ischemic stroke avoided was € 91,020 and € 24,722 at 5 and 10 years, respectively. The cost per life year gained for LAAC versus aspirin was € 22,694 at 5 years and decreased to € 5,859 at 10 years. cOnclusiOns: LAAC is a cost-effective alternative to aspirin therapy in patients with contraindications to warfarin. Cost offsets achieved with LAAC become considerably more pronounced over time. This analysis highlights the importance of considering the lifetime costs of stroke prevention in AF, especially as the probability of both stroke and bleeding increases with patient age. Objectives: To perform a cost-effectiveness analysis of rivaroxaban (once-daily) in the prevention of stroke and systemic embolism of patients with non-valvular atrial fibrillation (NVAF) and in patients sub-groups from the perspective of the Italian health care system (SSN). MethOds: A Markov model was developed with a lifetime timeframe where a hypothetic NVAF patients' cohort is treated with Vitamin-K antagonists (VKAs), antiplatelet drugs (ASA) or no therapy. Patients remain stable or progress towards other health states (ischemic or hemorrhagic stroke, myocardial infarction and bleedings) until death. The base case compares rivaroxaban with VKAs. In subgroup analyses, rivaroxaban is compared with patients at highest unmet medical need: 1. VKA patients with poor INR control, 2. patients under ASA or 3. not treated. Clinical data were derived from ROCKET-AF trial or a network meta-analysis. Utility data were retrieved from published literature. Health care resources consumption was valued using average regional tariffs in Italy. Since rivaroxaban price is not officially published, the price of the first novel oral anticoagulant approved in this indication in Italy was considered. Model outcomes are expressed in terms of incremental cost per quality adjusted life year (QALY) gained (ICER). Univariate and probabilistic sensitivity analyses were performed Results:
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In the base case, rivaroxaban showed to be cost-effective compared to VKA with an VKA-unsuitable, respectively) formed the basis of the analysis. Clinical events (ischemic strokes, hemorrhagic strokes, intracranial hemorrhages, other major bleeds, clinically relevant non-major bleeds, myocardial infarctions and cardiovascular hospitalizations) were modeled over a lifetime horizon based on the clinical efficacy of each comparator, as reported by two phase-III clinical trials (ARISTOTLE and AVERROES). Resource use with regards to patient monitoring was elicited via an experts' panel (cardiologists & internists). Cost calculations reflect the local clinical setting, and followed a third-party payer perspective (Euros, year 2013, discounted at 3%). Results: Apixaban was projected to reduce the occurrence of clinical events and increase quality adjusted life expectancy compared to warfarin and aspirin (an incremental increase of 0.225 and 0.274 QALYs per patient, respectively). Taking into account costs of medications, treatment and management of events, the incremental cost-effectiveness ratio for apixaban versus warfarin and aspirin was estimated at 12,154.6 € /QALY and 5,980.6 € /QALY gained, respectively. Extensive sensitivity analyses indicated that results were robust over a wide range of inputs. cOnclusiOns: Based on the results of this analysis, apixaban can be a cost-effective alternative to warfarin and aspirin for the management of VKA-suitable and VKA-unsuitable patients with NVAF, respectively, in Greece. Objectives: Intravascular ultra-sound (IVUS) allows physicians to generate a superior image of coronary arteries during percutaneous coronary interventions (PCI), providing a tomographic, 360-degree view of the arterial wall from the inside, which allows a more accurate and complete assessment than is possible with angiography. The purpose of this study was to understand the cost-effectiveness of IVUS compared with traditional angiography techniques in drug-eluting stent (DES) implantation, from the perspective of the Italian health system. MethOds: A Markov model was developed to extrapolate the comparative costs and outcomes of a theoretical population of 1000 patients undergoing DES implantation with traditional angiography alone, or in conjunction with IVUS. The model assesses cardiac events, including revascularisations and myocardial infarctions from a health system perspective. Outcomes with and without IVUS were based on a meta-analysis by Zhang et al (2013) . Because of limited clinical evidence to inform the long-term outcomes of IVUS compared with angiography, the model either assumes the benefit of IVUS is conferred only in the first year of treatment, or that the benefit is maintained permanently. Results: Using IVUS during PCI cost an average of € 542 per patient, and yields an additional 0.022 quality adjusted life years (QALYs) per patient. In a population of 1,000 patients, IVUS led to a reduction of 6.7 revascularisations and 5.9 less myocardial infarctions (MI) over the lifetime of a patient. When the revascularisation and MI benefit of IVUS is assumed to extend for the patient's lifetime, angiography with IVUS costs € 38 per patient and yields an additional 0.09 QALYs over a patient's lifetime; avoiding 13.4 MIs and 12.3 revascularisations per 1,000 patients. cOnclusiOns: IVUS appears to be a cost-effective addition to traditional angiography in DES placement in Italy, with the increased upfront cost of IVUS offset by reduced cardiac events in IVUS-treated patients over time. Objectives: Apixaban, dabigatran (150 mg BID and 110 mg BID) and rivaroxaban are three novel oral anticoagulants (NOACs) currently approved for stroke prevention and systemic embolism in non-valvular atrial fibrillation (NVAF) patients. The objective of this analysis was to assess the cost-effectiveness (CE) of apixaban against other NOACs for the prevention of stroke in patients with NVAF in Greece. MethOds: A Markov model that evaluated clinical events, quality adjusted life expectancy and costs for patients treated with apixaban or other NOACs formed the basis of the analysis. Clinical events (ischemic strokes, hemorrhagic strokes, intracranial hemorrhages, other major bleeds, clinically relevant non-major bleeds, myocardial infarctions and cardiovascular hospitalizations) were modeled for a lifetime horizon. Due to lack of head-to-head comparisons, efficacy and safety data was derived from an indirect treatment comparison (ITC). The key pivotal trials, ARISTOTLE, ROCKET-AF and RE-LY, all included warfarin as a comparator therefore allowing for an ITC. Resource use with regards to patient monitoring was elicited via a panel of experts (cardiologists & internists). Cost calculations reflect the local clinical setting and followed a third-party payer perspective (Euros, year 2013, discounted at 3%). Results: Apixaban was projected to reduce the occurrence of clinical events and increase quality-adjusted life expectancy and costs of treatment compared to other NOACs. Taking into account costs of medications, treatment and management of events, the incremental cost-effectiveness ratios for apixaban 5 mg BID versus dabigatran 150 mg BID, dabigatran 110 mg BID and rivaroxaban 20 mg QD were estimated at 15,403€ /QALY, 4,955€ /QALY and 10,130 € /QALY gained, respectively. Extensive sensitivity analyses indicated that results were robust over a wide range of inputs. cOnclusiOns: Based on the results of this analysis, apixaban can be a cost-effective alternative to other NOACs, for the prevention of strokes in patients with NVAF in Greece. using the UKPDS risk engine. Statin adherence was measured as pill days covered (PDC) in the IADB.nl pharmacy research database. Cost-effectiveness was measured in costs per quality-adjusted life-year (QALY) form the health carepayers' perspective. Results: For an average patient aged 60 at diagnosis, statin treatment was highly cost-effective at around € 2,300 per QALY. Favourable costeffectiveness was robust in sensitivity analysis. Differences in age and 10-year cardiovascular risk showed large differences in cost-effectiveness from more than € 100,000 per QALY to almost being cost saving. For the average patient aged 40 at diabetes diagnosis, statin treatment for primary prevention was not cost-effective. cOnclusiOns: Despite the non-adherence levels observed in actual practice, statin treatment is cost-effective for primary prevention in patients newly diagnosed with type 2 diabetes. Due to large differences in cost-effectiveness according to different risk and age groups, the efficiency of the treatment could be increased by targeting patients with relatively higher cardiovascular risk and higher ages.
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Objectives: Patients with a recent transient ischemic attack (TIA) or minor ischemic stroke who receive medicines have a 10-year risk of about 16% for any recurrent stroke. Non-invasive molecular imaging technologies are currently being developed to improve individual stroke risk prediction. We estimated the potential lifetime costeffectiveness of a novel imaging test for stroke prediction in an early stage of development. MethOds: Decision modelling was used to estimate the potential value of an add-on test that could identify which patients with a recent TIA or minor ischemic stroke should undergo surgery instead of receive medicines. The comparator was patient management according to Dutch guidelines. Test sensitivity and specificity were varied from 0-100% and its cost was set at € 350. Different age-and gender-specific subgroups were examined to see how much cost-effectiveness varied. Results: A perfect add-on test (100% sensitivity and specificity) for 60-year-old men appears to be cost-effective versus Dutch guidelines, with an estimated 0.61 QALY gain, € 3,986 cost increase, and an incremental cost-effectiveness ratio (ICER) of € 6,534/QALY gained. A test with sensitivity= 60% and specificity= 100% increases both health (0.14 QALYs) and costs (€ 2,888), resulting in an ICER of € 20,338/QALY gained. Similarly, a test with sensitivity= 100% and specificity= 60% increases both health (0.29 QALYs) and costs (€ 5,784) , resulting in an ICER of € 19,946/QALY gained. cOnclusiOns: An imaging test that improves risk prediction and therefore treatment decisions for patients with a recent TIA or minor ischemic stroke has the potential to optimize costeffectiveness by reducing the risk of recurrent stroke. However, reduced sensitivity or specificity of the test reduces its cost-effectiveness versus the Dutch guidelines. Developers must consider if the minimum level of accuracy required to be cost-effective is close to the maximum capability of the test. Model-based analyses are valuable in facilitating decisions about investments in the further development of a test.
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Objectives: At the population level, disease management programs (DMPs) for heart failure (HF) have proven to be effective in increasing quality-adjusted survival and reducing the rate of hospital readmission. However, a systematic assessment as to whether these outcomes could still be improved upon by tailoring the content and structure of such DMPs to the risk profile of the individual patient has not yet been conducted. Using data from a previously conducted randomized controlled trial, the purpose of this study was to explore the clinical and health economic consequences of assigning different DMPs to different risk categories of HF patient. MethOds: The analysis was conducted alongside the COACH study, in which 1023 patients were randomly assigned to one of three DMPs: care-as-usual (routine follow-up by a cardiologist), basic additional support by a nurse specialized in HF management (HF-nurse), and intensive additional support by an HF-nurse. The Subpopulation Treatment Effect Pattern Plot (STEPP) methodology was applied to graphically establish suitable cutoffs for stratifying patients into different risk categories based on their predicted 18-month mortality risk. Separate cost-effectiveness analyses were subsequently performed within each of these strata to determine per risk category the DMP that would be optimal in terms of survival time and costs. Results: Based on the STEPP analysis, a cut-off of 0.17 was selected to classify 346 (33.8%) patients as low risk and 677 (66.2%) patients as high risk. At a threshold value of € 10,000 per life-year, this resulted in an 82.9% probability that intensive support would be optimal for low-risk patients and an 83.6% probability that basic support would be optimal for high-risk patients. cOnclusiOns: Assigning different DMPs to different risk groups of patient improved outcomes and reduced costs. Tailoring the content and structure of such programs to the risk profile of the individual patient seems therefore desired. Objectives: Dabigatran was recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) in March 2011 for the treatment of non-valvular atrial fibrillation (NVAF) but was not listed on the Pharmaceutical Benefits Scheme (PBS) for over two years. This analysis examines the cost-effectiveness of dabigatran and the opportunity cost of delayed reimbursement from a societal perspective. MethOds: This analysis estimated the costs for dabigatran compared with warfarin and a mixed comparator (warfarin/aspirin/untreated) reflective of current ICER of € 11,000/QALY which is below the threshold deemed acceptable from Italian payers (25.000€ -40.000€ ). In the subgroups analyses, rivaroxaban demonstrated to be a dominant strategy (more effective and less costly). Sensitivity analyses showed the robustness of the results. cOnclusiOns: Rivaroxaban is a cost-effective alternative to VKA and is cost-saving for the SSN in the treatment of NVAF patients at highest unmet medical need. Boehringer-Ingelheim GmbH, Ingelheim Am Rhein, Germany Objectives: To estimate the cost-effectiveness of dabigatran etexilate (dabigatran) for the secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) from the perspective of the UK National Health Service. MethOds: A Markov model was developed to estimate costs and outcomes over the lifetime of a cohort of patients receiving either dabigatran (150mg given orally, twice daily) or placebo for 6 months after having completed 6 to 18 months of anticoagulation treatment for a DVT or PE. Modelled events included recurrent DVT and PE, major bleeding (including long-term disability from intracranial haemorrhage), clinically relevant non-major bleeding, myocardial infarction, unstable angina, pulmonary hypertension, severe postthrombotic syndrome, and death. Efficacy and safety parameters were based on the RE-SONATE study; the period of follow-up was 6 months with an extension to 18 months. Probabilities of recurrent DVT and PE after trial follow-up were based on a prospective cohort study of 1,626 patients followedup for a median of 50 months and were assumed to be equivalent in both treatment groups. Utility estimates were based on EQ-5D data collected in dabigatran trials and published literature. The mean duration of therapy was based on the RE-SONATE study; other costs were based on NHS Reference Costs and published literature. Costs and outcomes were discounted at 3.5% per annum. Univariate and probabilistic sensitivity analyses were performed. Results: In the base-case analysis, mean total costs for dabigatran and placebo patients were £7,147 and £7,520 respectively; mean QALYs were 13.089 and 13.070 respectively. Dabigatran was dominant; the probability of cost-effectiveness at a willingness-to-pay threshold of £20,000 per QALY was 63%. In univariate sensitivity analysis, dabigatran was dominant in all analyses. cOnclusiOns: This analysis suggests that dabigatran is likely to be costsaving compared to placebo for the secondary prevention of DVT and PE in the UK. Objectives: Statins are the standard treatment for cardiovascular disease (CVD) prevention however, with limited effect on triglyceride (TG) and high-density lipoprotein-cholesterol (HDL-C) in mixed hyperlipidemia. Fenofibric acid (FA) is approved for co-administration with statins to reduce TG and increase HDL-C in patients with mixed hyperlipidemia at goal for LDL-C with statins. This study assesses the costeffectiveness of FA combined with low (LDS) or medium (MDS) dose statins versus low, medium or high (HDS) dose statins alone in the prevention of CVD in Taiwanese patients with type 2 diabetes and mixed hyperlipidemia. MethOds: A 5-healthstate Markov model for diabetic patients with mixed hyperlipidemia already treated with statin (TG:250mg/dl; HDL-C:35mg/dl; LDL-C:115mg/dl; TC:200mg/dl) was developed, using a lifetime horizon with annual cycles. PROCAM (first event) and Framingham (subsequent event) risk equations were used. Effects on TG, HDL-C and TC for each comparator were derived from pooled simvastatin, atrovastatin and rosuvastatin trials. Drug and event costs were based on official national databases. Annual discounting (5%) was applied to outcomes and costs. Incremental cost (€ ) per Quality of Life Gained (QALYG) was calculated from the Taiwanese Bureau of National Health Insurance perspective. Results: Compared to LDS and MDS, treatment with FA+LDS resulted in higher costs (€ 2,225; € 1,676) but more QALYG (0.311; 0.064), resulting in an incremental cost-effectiveness ratio of € 7,161/QALYG and € 26,375/QALYG respectively. Compared to HDS, FA+LDS costs were lower with slightly less QALYG (ICER: € 183,490/QALYG). Compared to FA+MDS, FA+LDS was dominant with lower costs (-€ 900) and higher QALYG (0.004). Sensitivity analyses showed robustness of the results. The probability for FA+LDS being cost-effective (< GDP threshold € 45,400) is 100% for both, LDS and MDS. cOnclusiOns: In this specific mixed hyperlipidemia population, FA+LDS is likely to be a cost-effective alternative to LDS or MDS alone, potentially allowing for lower statin doses in preventing CVD.
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